Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sublingual Tablets of Grass Pollen Allergen Extract

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients 18-50 years old~* grass pollen rhinoconjunctivitis of at least 2 years.~* positive specific skin prick test and a specific IgE dosage level of at least 0.70 kU/L at screening.~* written consent~* a positive response to the baseline challenge test (RTSS reaches 7 at one time-point at least during baseline challenge)~Exclusion Criteria:~* Allergic rhino-conjunctivitis due to a co-sensitisation, likely to significantly change the symptoms of the subject throughout the study~* Asthma requiring treatment other than short-acting beta-2 inhaled agonists.~* Desensitisation treatment for grass pollen in the previous five years and current immunotherapy with another allergen.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).